CING
Cingulate
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
Consensus Rating "Strong Buy"
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CING
Cingulate Inc.
A biopharmaceutical company that develops Precision Timed Release platform to treat Attention Deficit Hyperactivity Disorder
1901 W. 47th Place, Kansas City, KS 66205
--
Cingulate Inc., was incorporated in Delaware on December 14, 2012. The Company is a clinical-stage biopharmaceutical company leveraging its proprietary Precision Time-Release (PTR) drug delivery platform technology to build and advance a next-generation drug pipeline designed to improve the lives of patients with common diagnostic diseases. The company's PTR platform incorporates a proprietary Erosion Barrier Layer (EBL) designed to allow the release of APIs at specific, predetermined time intervals, unlocking the potential of once-daily, multi-dose tablets.
Company Financials
EPS
CING has released its 2024 Q3 earnings. EPS was reported at -1.83, versus the expected -2.36, beating expectations. The chart below visualizes how CING has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
